IDOR 1134 9712
Alternative Names: IDOR-1134-9712Latest Information Update: 14 Feb 2025
At a glance
- Originator Idorsia Pharmaceuticals
- Developer Idorsia Pharmaceuticals; Unknown
- Class Antifibrotics
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cystic fibrosis